What is Cibus?
Cibus operates at the intersection of biotechnology and agricultural science, positioning itself as a leader in precision gene editing. The company has developed the Rapid Trait Development System, or RTDSTM, a versatile platform designed to accelerate the creation of beneficial plant traits. By focusing on the development of healthier food profiles and more resilient crop varieties, Cibus addresses critical global food security challenges. Its market position is defined by a commitment to non-transgenic innovation, which allows for the development of crops that meet both consumer demand for nutritional quality and the agricultural sector's need for high-yield, climate-adaptive solutions.
How much funding has Cibus raised?
Cibus has raised a total of $246.9M across 12 funding rounds:
Private Equity
$2.1M
Private Equity
$13.6M
Debt
$4M
Private Equity
$13.5M
Debt
$4.3M
Private Equity
$57M
Series B
$57M
Private Equity
$19.1M
Series C
$70M
Debt
$1M
Private Equity (2011): $2.1M, investors not publicly disclosed
Private Equity (2013): $13.6M, investors not publicly disclosed
Debt (2014): $4M, investors not publicly disclosed
Private Equity (2014): $13.5M, investors not publicly disclosed
Debt (2015): $4.3M, investors not publicly disclosed
Private Equity (2015): $57M, investors not publicly disclosed
Series B (2017): $57M, investors not publicly disclosed
Private Equity (2017): $19.1M, investors not publicly disclosed
Series C (2018): $70M with participation from Fidelity Management and Research Company, Cormorant Asset Management, and Alexandria Venture Investments
Debt (2020): $1M led by PPP
Key Investors in Cibus
Fidelity Management and Research Company
A global financial services powerhouse providing comprehensive wealth management and institutional investment solutions, known for its long-term commitment to high-growth technology and life sciences sectors.
Cormorant Asset Management
A specialized life sciences investment firm that leverages deep fundamental scientific expertise to support innovative private and public companies within the biotech and healthcare industries.
Alexandria Venture Investments
The strategic venture capital arm of Alexandria Real Estate Equities, focusing on providing capital and infrastructure support to transformative companies in the life sciences and biodefense ecosystems.
What's next for Cibus?
With a robust history of capital accumulation, Cibus is now positioned to transition from its foundational research and development phase into a broader commercialization strategy. The recent influx of capital is expected to accelerate the deployment of the RTDSTM platform across diverse crop portfolios, enhancing the company's competitive moat in the global ag-tech landscape. Future strategic initiatives will likely prioritize the scaling of operational capacity and the expansion of partnerships with major agricultural stakeholders to integrate these advanced traits into the global supply chain. As the regulatory environment for gene-edited crops continues to evolve, Cibus remains well-capitalized to navigate these shifts and solidify its status as a cornerstone of modern agricultural biotechnology.
See full Cibus company page
